呼吸道合胞病毒（Respiratory Syncytial Virus, RSV）作為引起急性下呼吸道感染（ALRTIs）的主要原因之一，每年導(dǎo)致全球約3.31億人發(fā)生呼吸道感染。然而，就是這樣一個常見且早已被發(fā)現(xiàn)的呼吸道病毒，其疫苗的研發(fā)卻十分坎坷，以至于至今仍無一款成熟的RSV疫苗問世。

此前的數(shù)十年間，科學(xué)家們不曾停止對于RSV疫苗的研究與開發(fā)，但均以失敗告終。究其原因，可能是因?yàn)镽SV病毒結(jié)構(gòu)的特殊性。病毒表面的融合蛋白（fusion protein , F）和粘附蛋白（attachment protein, G）因在病毒入侵過程中的關(guān)鍵作用成為病毒研究的理想靶點(diǎn)，而其中G蛋白變異較多相對不穩(wěn)定，F(xiàn)蛋白也存在Pre到Post構(gòu)象轉(zhuǎn)變影響其穩(wěn)定性。

貨號：DVV02811

產(chǎn)品鏈接：http://www.antibodysystem.com/product/9005.html

寄主物種：Human

形式：Liquid

存儲緩沖區(qū)：0.01M PBS, pH 7.4.

濃度：1 mg/ml

純度：>95% by SDS-PAGE.

克隆性：Monoclonal

應(yīng)用：Research Grade Biosimilar

儲存：Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.

聯(lián)系方式：027-65279366

為了克服這一障礙，科學(xué)家們對RSV F蛋白的蛋白結(jié)構(gòu)及其抗體進(jìn)行了研究，發(fā)現(xiàn)該蛋白表面至少存在7個完全不同的抗原表位，并成功篩選到可以與不同表位結(jié)合的抗體，分別為φ site_D25/5C4/AM22，I site_131-2A/2F，II site_motavizumab/palivizumab，III site_MPE8，IV site_101F/mAb19，V site_hRSV90。其中識別IV表位的101F、識別II表位的palivizumab和識別I表位的131-2A抗體可以同時識別F蛋白的pre和post構(gòu)象，識別φ表位的D25抗體只與Pre構(gòu)象的F蛋白發(fā)生結(jié)合，識別III表位的MPE8抗體則偏好識別Pre構(gòu)象，與Post構(gòu)象具有較弱的結(jié)合活性。2010年，Kwakkenbos研究團(tuán)隊(duì)篩選獲得單克隆抗體AM14，其識別的抗原表位位于F-pre蛋白近赤道區(qū)域，橫跨兩個單體，可特異性識別F-pre三聚體結(jié)構(gòu)，且被證明與此前中和效果最佳的D25抗體具有相似的中和活性和更快的動力學(xué)性質(zhì)。

參考文獻(xiàn)：

Dissociation of the respiratory syncytial virus F protein-specific human IgG, IgA and IgM response. PMID: 33574352

Cleavage of the respiratory syncytial virus fusion protein is required for its surface expression: role of furin. PMID: 10930660

Prefusion F, Postfusion F, G Antibodies, and Disease Severity in Infants and Young Children With Acute Respiratory Syncytial Virus Infection. PMID: 29029312

Intracellular processing of the human respiratory syncytial virus fusion glycoprotein: amino acid substitutions affecting folding, transport and cleavage. PMID: 1375280

Fusion glycoprotein of human parainfluenza virus type 3: nucleotide sequence of the gene, direct identification of the cleavage-activation site, and comparison with other paramyxoviruses. PMID: 3012869

Membrane-associated respiratory syncytial virus F protein expressed from a human rhinovirus type 14 vector is immunogenic. PMID: 11277694

Alkaline phosphatase fusions to the respiratory syncytial virus F protein as an approach to analyze its membrane topology. PMID: 2558867

Clinical Potential of Prefusion RSV F-specific Antibodies. PMID: 29054341

A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism. PMID: 26333350

Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. PMID: 24179220